Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter F Riesen

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Praxis|May 29, 2019
Walter F Riesen
Atherosclerosis|December 22, 2009
Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosisWalter F Riesen
Praxis|February 2, 2022
[Pleiotropic Effects of Statins - What Is Their Clinical Significance?]Walter F Riesen
Cardiology|May 11, 2016
Icosabutate, a More Potent Form of Omega 3 Fatty Acids, Shows Promise in Lowering TriglyceridesWalter F Riesen
Praxis|April 15, 2016
[A new view of arteriosclerosis development points the way to new therapy concepts]Walter F Riesen
Revue Medicale Suisse|May 8, 2008
[What are the biomarkers of atherosclerosis and cardiovascular risk?]Walter F Riesen
Praxis|August 24, 2017
Walter F Riesen
Swiss Medical Weekly|July 26, 2008
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemiaWalter F Riesen, Georg Noll, Roger Dariolo, et al.
Current Medical Research and Opinion|March 10, 2004
Lipid-lowering therapy: strategies for improving complianceWalter F Riesen, Roger Darioli, Georg Noll
Cardiovascular Drugs and Therapy|December 31, 2005
Economic impact of hyperhomocysteinemia in SwitzerlandThomas D Szucs, Andreas Käser, Walter F Riesen
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Praxis|May 29, 2019
Walter F Riesen
Atherosclerosis|December 22, 2009
Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosisWalter F Riesen
Praxis|February 2, 2022
[Pleiotropic Effects of Statins - What Is Their Clinical Significance?]Walter F Riesen
Cardiology|May 11, 2016
Icosabutate, a More Potent Form of Omega 3 Fatty Acids, Shows Promise in Lowering TriglyceridesWalter F Riesen
Praxis|April 15, 2016
[A new view of arteriosclerosis development points the way to new therapy concepts]Walter F Riesen
Revue Medicale Suisse|May 8, 2008
[What are the biomarkers of atherosclerosis and cardiovascular risk?]Walter F Riesen
Praxis|August 24, 2017
Walter F Riesen
Swiss Medical Weekly|July 26, 2008
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemiaWalter F Riesen, Georg Noll, Roger Dariolo, et al.
Current Medical Research and Opinion|March 10, 2004
Lipid-lowering therapy: strategies for improving complianceWalter F Riesen, Roger Darioli, Georg Noll
Cardiovascular Drugs and Therapy|December 31, 2005
Economic impact of hyperhomocysteinemia in SwitzerlandThomas D Szucs, Andreas Käser, Walter F Riesen
Pageof 3